ClinicalTrials.gg
CompletedNCT06972212Updated Jul 3, 2025

Pharmacodynamic Study of 100mg Suzegtrigine vs Placebo in Healthy Male Adults

An Early Phase 1 interventional study of suzetrigine 100mg and Placebo in Pain Detection and Pain Threshold, sponsored by Latigo Biotherapeutics. Completed at 1 site in New Zealand. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-03.

Sponsored by Latigo Biotherapeutics · Early Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing suzetrigine in Pain — 4 open to participants now, 4 under way, 2 of them phase 3. suzetrigine · Pain.

Enrollment
18th of 21
20 · median 50
Started
2025
with 4 others
Phase 1
15 of 21
none open now
Registered
13th of 21
by date
Lead sponsor
1 of 21
Latigo Biotherapeutics

Among the 21 studies testing suzetrigine in Pain, this one is the 18th largest by enrollment, is one of 5 that started in 2025, is one of 15 in phase 1, and was the 13th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

4 of the 21 studies testing suzetrigine in Pain are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About suzetrigine

suzetrigine: first FDA approval 2025 (JOURNAVX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing suzetrigine in Pain, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled within-participant crossover study in healthy male participants 18-55 years of age to assess pain tolerance during a cold pressor test.

The study will be conducted at a single center in New Zealand.

03

Conditions studied

  • Pain Detection
  • Pain Threshold

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male participants aged 18 to 55 years, inclusive, at the time of signing the .
  2. Overtly healthy with no abnormalities based on the medical history, physical examinations, clinical laboratory evaluations, and 12-lead that, in the opinion of the investigator, would affect participant safety.
  3. (BMI) within the range of 18-32 kg/m2 (inclusive).
  4. Male participants are eligible to participate if they agree to refrain from donating semen. Plus, agree to use a male condom when having sexual intercourse with woman of or women who are currently pregnant.
  5. Capable of giving signed informed consent.
  6. Willing to undergo Pain Tolerability Assessments using the cold pressor procedure.

Exclusion criteria

Exclusion Criteria:

  1. Inability to take oral medications or gastrointestinal abnormalities potentially impacting absorption.
  2. cardiovascular, hematological, renal, hepatic, pulmonary, endocrine, gastrointestinal, immunological, dermatological, neurological, or psychiatric disease which could interfere with, or the treatment for which might interfere with, the conduct of the study or which would, in the opinion of the investigator, unacceptably increase the participant's risk by participating in the study.
  3. (ALT) or aspartate aminotransferase (AST), >1.5 x (ULN) at Screening.
  4. Total > 1.5 x ULN (for participants with known Gilbert's syndrome, a total bilirubin >1.5 x ULN is allowed provided the direct bilirubin is ≤1.5 x ULN)) at Screening.
  5. Estimated (eGFR) \<80 mL/min based on serum creatinine levels using the 2021 chronic kidney disease epidemiology (CKD-EPI) creatinine equation at Screening. The CKD-EPI 2009 equation may be used per site standard practice.
  6. Creatinine phosphokinase is ≥ 2 × ULN at Screening.
  7. Any of the protocol defined abnormalities on 12-lead or blood pressure (BP) at Screening, confirmed by repeat.
  8. Use of prescription drugs ≤ 14 days (or 5 half-lives of the drug, whichever is longer) prior to Day 1, use of over-the-counter drugs, herbal medications, or vitamin supplements ≤ 7 days (or 5 half-lives of the drug, whichever is longer) prior to Day 1 or use of antibiotics and systemic ≤ 28 days prior Day 1. The Sponsor may allow exceptions only if the medication's administration is deemed unlikely to confound safety or efficacy.
  9. Any vaccination ≤ 14 days prior to Day 1 or anticipated vaccination while participating in the study.
  10. Receipt of an product or device, or participation in a drug research study ≤ 28 days (or 5 half-lives of the drug, whichever is longer) prior to Day 1.
  11. Receipt of an investigational biologic / monoclonal antibody within 180 days (or 5 half-lives, whichever is longer) prior to Day 1.
  12. Positive for Coronavirus Disease 2019 (COVID-19) suggesting active infection at Screening or on Day 1.
  13. Positive (HIV) at Screening.
  14. Presence of any condition for which administration of a sodium channel blocker is .
  15. Smoking or vaping of tobacco or nicotine, or any other use of tobacco or any products containing nicotine ≤ 14 days prior to Day 1.
  16. Consumption of alcohol within 48 hours prior to Day 1 and/or food and beverages containing methylxanthines (caffeinated coffee, caffeinated tea, caffeinated soda, and chocolate) within 48 hours of Day 1, and grapefruit, grapefruit juice, Seville oranges, or Seville orange juice ≤ 14 days prior to Day 1.
  17. Positive urine drug screen, urine cotinine test, or alcohol breath test at Screening or on Day 1.
  18. Past or current history or evidence of alcohol abuse, regular use of more than 2 units of alcohol per day (1 unit of alcohol = 150 mL of wine, 360 mL of beer, or 45 mL of alcohol 40%), use of any illicit drugs (such as cocaine, phencyclidine [PCP], and crack) within 6 months of Screening, and/or a positive screen for substances of abuse or alcohol at Screening or on Day 1.
  19. Past or current history or evidence of dependence on recreational drug use (eg, marijuana), use of recreational drugs ≤ 28 days prior to Day 1, or positive test result at Screening or on Day 1.
  20. Donation or loss of over 500 mL blood ≤ 3 months prior to Day 1.
  21. Use of moderate or strong CYP 3A4 inhibitors or inducers.
  22. Has known psychiatric disorders that would interfere with the cooperation with the requirements of the study.
  23. Participant is under legal custodianship.
  24. Pain conditions that may require analgesic treatment during the study or history of opioid medication use
  25. Hand/arm/skin conditions impacting ability to participate in cold pressor assessment.
  26. Recent serious injury, surgical procedure, or medical condition which, in the opinion of the investigator, unacceptably increases the participant's risk by being included in the study.
  27. Meets protocol defined Pain Tolerance Threshold () in any of the 5 predose cold pressor tests
  28. Any relative or absolute contraindication to suzetrigine as outlined in the prescribing information for Journavx.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
20 participants (actual)

Study arms

  • Other
    Schedule A

    participants receive suzetrigine 100mg in treatment period 1, and receive placebo in treatment period 2

    Drug: suzetrigine 100mg · Other: Placebo

  • Other
    Schedule B

    participants receive placebo in treatment period 1, and receive suzetrigine 100mg in treatment period 2

    Drug: suzetrigine 100mg · Other: Placebo

Interventions

  • Suzetrigine is an inhibitor of the NaV1.8 voltage-gated sodium channel and FDA approved for the treatment of moderate-to-severe acute pain in adults

    Also known as: Journavx

  • OtherPlacebo

    biologically inactive placebo comparator

06

What researchers measure

Primary outcomes

  1. Change from baseline pain score after dosing with suzetrigine vs. placebo

    Numerical Pain Rating Scale (NPRS) will be assessed during Cold Pressor Tests at various time points for time to reach Pain Detection Threshold (PDT) and time to reach Pain Tolerance Threshold (PTT)

    Time frame: 0-24 hours during each treatment period

  2. Time to reach Pain Detection Threshold (PDT) and Pain Tolerance Threshold (PTT) after dosing with suzetrigine vs placebo

    Stopwatches will be used during each cold pressor test to determine time for subject to reach PDT and PTT

    Time frame: 0-24 hours during each treatment period

07

Study locations

1 site
  • New Zealand Clinical Research, Christchurch
    Christchurch, New Zealand
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Jun 2025, 0 months.

Of 104 industry-sponsored phase 1 interventional studies under Pain, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 9. This study's 0 months is below that.

Counting every sponsor, half of 220 studies reached it within 9 months; a quarter within 3 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2025
First posted
May 14, 2025
StartActual
Jun 4, 2025
Primary completionActual
Jun 28, 2025
CompletionActual
Jun 28, 2025
Last update
Jul 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06972212
Lead sponsor
Latigo Biotherapeutics
Responsible party
Sponsor
First posted
May 14, 2025
Start date
Jun 4, 2025
Primary completion
Jun 28, 2025
Completion
Jun 28, 2025
Last update
Jul 3, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Suzetrigine

Start the discussion